Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20570)	5/12/1998 7:53:00 AM
From: squetch	Read Replies (5) \| Respond to of 32384

SRGN psoriasis info. They still don't know where to dose it, but response seems good. Safety?? I believe estimate was 6 mill patients. >>The accumulated data from the first two psoriasis studies indicated that DAB389IL-2 induced meaningful clinical responses in as many as 50% of psoriasis patients who had previously been treated with multiple other therapies. Tolerability issues suggest that three doses per week for four weeks, especially at the higher doses tested, may be too frequent. Other observations indicate that clinical improvement after a single five-day treatment per month may induce maximum response two weeks after administration. These data suggest that monthly administration may not be frequent enough. Therefore, the Company designed a third psoriasis trial to evaluate the safety and effectiveness of administration of the lower dose range of DAB389IL-2 on a bi-weekly schedule. This Phase I/II dose-escalation study is ongoing. However, even if DAB389IL-2 is found to be effective in this patient population, the Company does not yet know if the side effect profile, which may be acceptable in cancer, will be considered tolerable by a majority of psoriasis patients and their physicians.<<